Kornimate/medical-research-clean huggingface dataset:
the effect of reducing soreness in marathon runners

Conditions: Contracture of Muscle, Thigh

Summary: delayed onset muscle soreness is defined as the sensition of pain and discomfort in skeletal muscles that occurs after eccentric muscle actions or strenuous exercise like a marathon.

there is a growing body of clinical evidence which shows that noninvasive, nonpharmacologic pulsed electromagnetic fields have many clinical effects. pulsed electromagnetic fields have shown to reduce pain in different groups of patients. this concerns patients with osteoarthritis, rheumatoid arthritis, diabetic neuropathy, fibromyalgia, distal radius fractures, pelvic pain and postoperative patients. a marathon is a muscular strain. physiologic effects of a marathon involves muscular and connective tissue damage which initiates an inflammatory response as well as release of metabolic factors like lactate and free radicals, intracellular metabolites and by-products of proteolysis. the objective of this study was to investigate the efficacy of pulsed electromagnetic fields compared to placebo in reducing delayed onset muscle soreness in marathon runners.

Eligibility criteria:
inclusion criteria: * completion of a marathon * age \> 18 years exclusion criteria: - unable to read and speak danish

Keywords: pain delayed onset muscle soreness pulsed electromagnetic field marathon
study with cy, pembrolizumab, gvax pancreas vaccine, and sbrt in patients with locally advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to t cells), gvax (pancreatic cancer vaccine), and sbrt (focused radiation) is effective (anti-tumor activity) and safe in patients with locally advanced pancreatic cancer.


Eligibility criteria:
inclusion criteria: 1. locally advanced pancreatic adenocarcinoma 2. patients must have received mfolfirinox or gemcitabine/ abraxane based chemotherapy for 4 cycles with last dose of therapy between 2-5 weeks of study enrollment. 3. age \>18 years 4. no metastatic disease 5. ecog performance status of 0 to 1 6. adequate organ function as defined by study-specified laboratory tests 7. patients must be able to have fiducials placed for sbrt 8. must use acceptable form of birth control through the study 9. signed informed consent form 10. willing and able to comply with study procedures exclusion criteria: 1. patients who have been off of mfolfirinox or gemcitabine/abraxane therapy for more than 49 days 2. patients who have had more than one line of chemotherapy 3. patients with uncontrolled intercurrent illness, including but not limited to ongoing or active infection, systematic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric condition that would limit compliance with study requirements 4. patient who have had prior treatment with il-2, interferon, anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, anti-ox-40, anti-cd40, or anti-ctla-4 antibodies 5. patients receiving active immunosuppressive agents or chronic use of systemic corticosteroids within 14 days prior to first dose of study drug 6. patients who have received growth factors, including but not limited to granulocyte-colony stimulating factor (g-csf), granulocyte macrophage-colony stimulating factor (gm-csf), erythropoietin, etc. within 14 days of study drug administration 7. patients with history of any autoimmune disease:inflammatory bowel disease, (including ulcerative colitis and crohn's disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematous (sle) autoimmune vasculitis, cns or motor neuropathy considered to be of autoimmune origin. 8. patients who have known history of infection with hiv, hepatitis b, or hepatitis c 9. patients with evidence of interstitial lung disease 10. patients on home oxygen 11. patients with oxygen saturation of \<92% on room air by pulse oximetry 12. pregnant or lactating 13. conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures

Keywords: vaccine immunotherapy antibody pd-1 radiation
a study of overall survival in participants with unresectable hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms

Summary: the primary purpose of this study to continue follow-up of participants enrolled in the study e7080-m081-504 (nct03663114) of lenvima capsules and to evaluate the overall survival of participants with hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: - all participants enrolled in the study e7080-m081-504 with informed consent to participate in this study. exclusion criteria: * participants who do not have unresectable hepatocellular carcinoma * participants who have not given informed consent or have withdrawn consent to participation * participants with a history of hypersensitivity to any ingredient of lenvima * pregnant or possibly pregnant women * participants previously treated with lenvima (excluding those previously enrolled in the study e7080-m081-504 \[nct03663114\] at another clinical site).

Keywords: hepatocellular carcinoma lenvatinib mesilate lenvima len03t
evaluation of antral ultrasonography for full stomach diagnosis before pediatric surgical emergencies

Conditions: Gastric Content; Full Stomach Status

Summary: this study evaluates antral ultrasonography for the diagnosis of full stomach before surgical emergencies in pediatric population. preoperative ultrasonographic antral evaluation is compared to peroperative gastric aspirate with nasogastric tube.


Eligibility criteria:
inclusion criteria: * surgical emergency procedure * asa i-ii exclusion criteria: * ultrasound antrum assessment not possible * no nasogastric tube during surgery * vital emergency * patient from critical care ward * time between ultrasound assessment and gastric content collecting up to 20min * child and/or parents doesn't/don't want to participate in the study * personal medical history of gastric or oesophagus desease

Keywords: ultrasonography aspiration emergency children antrum
overcoming analgesic tolerance to tens

Conditions: Pain

Summary: the purpose of this study is to determine if changing the frequency or intensity of transcutaneous electrical nerve stimulation (tens) can reduce the development of tolerance to tens treatment.

healthy adults will come daily for 5 consecutive days to the testing room. pressure pain thresholds (ppt) will be the outcome measure and will be used to measure the subject's pain threshold to deep mechanical pressure. subjects will push a button to stop the ppt test when they first begin to feel a sensation of pain. the ppt test will be done before tens application. the tens unit will be applied based on random assignment to 1 of 5 treatment types and subjects will not be told which group they are assigned to. those groups are: 1) placebo tens, 2) high frequency tens, 3) alternating frequency tens, 4) modulated frequency tens, or 5) high frequency tens with increased intensity daily. the tens unit will be applied for 30 minutes. after 20 minutes the ppt test will be completed a second time. this procedure will occur on all 5 consecutive days of testing. data will be measured and recorded by an assessor blind to subject group. blinding will be assessed at the end of testing on day 5.

Eligibility criteria:
inclusion criteria: * 18-65 years of age (yoa) * no current pain condition exclusion criteria: * pregnancy * cardiac pacemaker * currently experiencing pain * abnormal sensation in dominant forearm * history of seizures * prior tens use
vitamin d deficit in women with uterine fibroids

Conditions: Leiomyoma; Vitamin D Deficiency; Fibroid Uterus

Summary: determinate the level of vitamin d in blood, and evaluate the prevalence of deficit and insufficiency among patients with diagnosis of uterine fibroids

a cross-sectional prevalence study will be carried out, taking patients with a diagnosis of uterine fibroid in two hospitals; blood level of vitamin d will be taken to determine the proportion of patients with deficit and insufficiency; in addition, the number, size and type (according to the palm-coen classification) of the uterine fibroids in each patient will be analyzed.

Eligibility criteria:
inclusion criteria: * female * diagnosis of uterine fibroid exclusion criteria: * female with diagnosis of uterine fibroid under treatment with exogenous vitamine d
characterizing the role of pain sensitivity in acute to persistent low back pain

Conditions: Low Back Pain

Summary: this research study will examine whether enhanced pain sensitivity increases the risk of persistent low back pain. the study will address the highly prevalent and costly condition of persistent low back pain and a major obstacle for the implementation of clinical strategies to improve patient outcomes. the knowledge gained from this study may lead to a better understanding of the biological mechanisms that contribute to persistent low back pain and will inform future work to develop predictive measures of persistent low back pain risk, evaluative measures to examine treatment efficacy, and possibly biomarker assay(s) to identify patients who are at increased risk of persistent low back pain.

the specific aims (sa) of the proposed study are to: specific aim 1. characterize (a) the differences in pain sensitivity between incident cases and controls at low back pain onset and (b) changes in pain sensitivity over time in incident cases. h1.a incident cases will have increased pain sensitivity compared with controls at low back pain onset. h1.b incident cases will have increased pain sensitivity over time. specific aim 2. compare (a) genetic polymorphisms at low back pain onset between incident cases and controls and mrna expression of candidate genes at lbp onset and at 6 weeks between incident cases and controls; and (b) differential expression levels of candidate genes over time in incident cases. h2.a incident cases will have a higher frequency of polymorphisms and differential expression levels of candidate genes at low back pain onset compared with controls. h2.b examine expression levels of candidate genes over time in incident cases. specific aim 3. determine the contribution of enhanced pain sensitivity, cofactors (clinical/psychosocial/environmental), genetic polymorphisms, and mrna expression of candidate genes on the risk of persistent low back pain.

Eligibility criteria:
inclusion criteria: 1. 18-50 years of age; 2. diagnosed with an acute episode of nonspecific lbp present for \>24 hours but \<4 weeks duration and preceded by at least 1 pain-free month; and 3. comprehend english exclusion criteria: 1. \ 50 years of age; 2. chronic pain at another site or associated with a painful condition (eg., fibromyalgia, neuropathy, rheumatoid arthritis); 3. previous spinal surgery; 4. presence of neurological deficits; 5. history of comorbidities that affect sensorimotor function (eg., multiple sclerosis, spinal cord injury, diabetes); and 6. untreated psychological disorders (major depression, bipolar disorder, schizophrenia)

Keywords: low back pain pain sensitivity genes gene expression, quantitative sensory testing
management of ventilation acquired pneumonia caused by pseudomonas and acinetobacter organisms in a pediatric center

Conditions: Ventilation Acquired Pneumonia

Summary: the goal of this clinical trial is to determine the most effective empirical therapy of antibiotics for better ventilator-associated pneumonia control. the main question it aims to answer is: • which is better for clinical response single or combination empiric antibiotic therapies ?


Eligibility criteria:
inclusion criteria: -patients ranging from one month to twelve years old, who had been undergoing mechanical ventilation for over 48 hours and were diagnosed with ventillator associated pneumonia. 2.1.3. exclusion criteria: * patients with pneumonia prior to mechanical ventilation initiation. * patients who had been intubated for more than 24 hours before admission to the picu, or those transferred from other picus and were already receiving antibiotic therapy.

Keywords: ventilator-associated pneumonia pandrug-resistant extensively drug-resistant
relationship between morbimortality and basal activated clotting time (act) in patients undergoing vascular surgery

Conditions: Artery Disease, Peripheral; Aortic Diseases; Carotid Artery Diseases; Other Disease

Summary: check whether patients with higher comorbidity and risk of complication, estimated using the v (p) -possum score, acs nsqip and the asa classification, present higher baseline activated clotting time values.


Eligibility criteria:
inclusion criteria: * patients undergoing vascular surgery requiring intraoperative heparinization exclusion criteria: * pregnant women * sars-cov-2 pcr positive (performed 24-72h prior to surgery) * severe plaquetopenia \<50,000
study to evaluate ecallantide in paediatric patients with acute attacks of hereditary angioedema

Conditions: Hereditary Angioedema (HAE)

Summary: the primary objective of this study is: * assess the safety and tolerability of ecallantide in paediatric patients for acute attacks of hae the secondary objectives are: * evaluate the pharmacokinetic profile of ecallantide in paediatric patients treated for acute attacks of hae * assess the efficacy of ecallantide in paediatric patients treated for moderate to severe acute attacks of hae


Eligibility criteria:
inclusion criteria: 1. male or female from 2 years of age and prepubertal 2. physician diagnosis and history of hae (type i or ii) including laboratory results showing c1-1nh activity below the lower limit of normal or up to 15% above the lower limit of the normal range 3. present at the site with moderate to severe signs and symptoms of an acute attack of hae within 8 hours of recognition of the onset of the attack. spontaneous resolution of the attack must not have begun before the administration of study drug. 4. must have signed informed consent by parent or caregiver. exclusion criteria: 1. \<2 years of age or have reached puberty 2. received treatment with ecallantide within previous 72 hours 3. received an investigational drug or device, other than ecallantide, within 30 days prior to the screening visit 4. pharyngeal/laryngeal symptoms 5. mild attacks including mild edema of the extremities and mild abdominal attacks 6. are unable or unwilling to give informed consent (parent or caregiver) 7. any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or would preclude the patient from successful completion of the study
health-related quality of life in cases of cubital tunnel syndrome

Conditions: Cubital Tunnel Syndrome

Summary: this study aims to determine the health related quality of life (hrqol) (the physical, mental, emotional and social functioning) of patients with cubital tunnel syndrome following anterior intramuscular transposition, after one year.

as there are many different surgical procedures to address cubital tunnel syndrome, hrqol will be used to determine if anterior intramuscular transposition provides patients with positive outcomes. to measure hrqol 3 specific scales will be administered: 1. a generic scale, the short form-36 2. a condition specific scale, the patient-rated ulnar nerve evaluation (prune) 3. a utility scale, the euroqol, five dimension questionnaire these scales are widely reported in the literature, are valid, reliable and easy to fill out. using these scales we can determine hrqol as well as quality adjusted life years, which, allows us to do a cost-utility analysis (economic evaluation) on this specific procedure. patients will be asked to fill out the above mentioned questionnaires, as well as perform 2 performance tests (grip strength, and a moving 2-point discrimination test) at the following time points: 1. 1 week prior to surgery 2. 1 day prior to surgery 3. 3 months post surgery 4. 6 months post surgery 5. 12 months post surgery

Eligibility criteria:
inclusion criteria: * diagnosis of cubital tunnel syndrome confirmed with electromyography (emg) testing or ultrasound imaging * ability to comprehend english and complete health related quality of life questionnaires * willing to provide informed consent * age \> 18 years * not pregnant exclusion criteria: * prior ipsilateral cubital tunnel release * evidence of symptomatic clinical double crush syndrome confirmed by emg/nerve conduction study (ncs) * patients with rheumatoid arthritis, connective tissue disorder, tenosynovitis, or diagnosed neurological condition that could confound the assessment of health-related quality of life with regard to the affected arm and hand
dzd8586 in patients with relapsed or refractory cll/sll (tai-shan8)

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Summary: this study will treat patients with cll/sll whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. this study will assess the anti-tumor activity of dzd8586 as monotherapy. it will help to understand what type of side effects may occur with the drug treatment. it will also measure the levels of drug in the body.


Eligibility criteria:
inclusion criteria: participants who meet all the following criteria: 1. male and female ≥ 18 years of age. 2. ecog performance status 0-2. 3. confirmed diagnosis of relapsed or refractory cll/sll with indication for treatment. 4. adequate bone marrow reserve and organ system functions. 5. willing to comply with contraceptive restrictions. exclusion criteria: participants who meet any of the following criteria: 1. cns involvement or richter transformation. 2. stem cell transplantation, cell therapy, or gene therapy within 90 days. approved small molecule therapy within 5 half-lives, monoclonal antibodies and antibody-drug conjugates within 28 days. 3. major surgery or significant traumatic injury within 4 weeks. live attenuated vaccines or viral vector vaccines within 4 weeks. 4. take vitamin k antagonists or take more than 2 anticoagulants or antiplatelet drugs at the same time. take proton pump inhibitors or strong cyp3a inhibitors or inducers. 5. active infection. 6. clinically significant cardiac disorders or abnormalities. history of thrombotic diseases, stroke or intracranial hemorrhage within 6 months. 7. nausea and vomiting not controlled or chronic gastrointestinal diseases, unable to swallow the formulated product or previous bowel resection that would preclude adequate absorption. 8. another malignancy within 2 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or non-melanomatous skin cancer. 9. women who are breast feeding. 10. history of hypersensitivity to active or inactive excipients of dzd8586 or drugs with a similar chemical structure or class.
monitoring drug-induced myocarditis (carditox)

Conditions: Myocarditis; Myocardial Failure; Myocardial Dysfunction

Summary: several drugs and chemotherapies seem to induce myocarditis. this study investigates reports of myocarditis, including the international classification of disease icd-10 for treatments in the world health organization (who) global individual case safety report (icsr) database (vigibase).

several drugs and chemotherapies seem to have an impact on the myocardium and are responsible of myocarditis. those are poorly described, due to the modification of the pharmacopeia, and the recent recognition of several of these adverse events. this study investigates the main characteristics of patients affected by myocarditis side effect imputed to drugs. a causality assessment according to the who-umc (world health organization - uppsala monitoring center) is systematically applied.

Eligibility criteria:
inclusion criteria: * case reported in the who's pharmacovigilance database till 25/02/2019 exclusion criteria: * chronology not compatible between the drug and the toxicity

Keywords: myocardial toxicity chemotherapies drugs
safety and effectiveness study for a needle guidance system in lung biopsies

Conditions: Lung Diseases

Summary: this study is designed to provide clinical data regarding safety and clinical effectiveness of the actisight needle guidance system in assisting radiologically guided percutaneous needle biopsy or aspiration of pulmonary lesions, which is a common procedure.

this will be a prospective, single-arm study. at least three centers in canada will participate in the study and at least 4 different experienced staff radiologists will perform the procedures for the study. a total of forty eight (48) consecutive subjects meeting the eligibility criteria, scheduled for clinically indicated ct guided lung biopsy or aspiration procedure at the participating centers will be invited to enroll in the study. to ensure diversity in the study population, consecutive patients will be enrolled in the following groups until these groups are fully enrolled: lesion size ≥1.0 cm and ≤ 1.5 cm: 10 patients; lesion size \>1.5 and ≤ 3.0 cm: 19 patients; lesion size \>3.0 cm: 19 patients. a maximum of 24 patients will be enrolled at each center. informed consent will be signed prior to the procedure. subject data collection on the day of the procedure will include demographics, relevant medical history and vital signs. enrolled subjects will undergo ct guided percutaneous lung aspiration and/or biopsy as clinically indicated by a qualified physician, utilizing the actisight needle guidance system. subjects will be followed-up as outlined below to assess adverse events related to the procedure. a subject's enrollment in the study will be completed after the follow-up visit or after resolution of any procedure related adverse event. a procedure difficulty classification is defined for this study, based on existing literature. difficulty levels for all procedures will be recorded and included in the final report.

Eligibility criteria:
inclusion criteria: * male or female subjects, 18 years of age or older at the time of enrollment; * subjects scheduled for clinically indicated ct guided percutaneous lung aspiration/biopsy; * written informed consent to participate in the study; * ability to comply with the requirements of the study procedures; * verified home address and phone number to facilitate study follow-up. exclusion criteria: * significant coagulopathy that cannot be adequately corrected; * subjects who participated in an active stage of any drug, intervention or treatment trial within 30 days of enrollment; * subjects with preexisting conditions which, in the opinion of the investigator, interfere with the conduct of the study; * subjects who are uncooperative or cannot follow instructions; * mental impairment that may preclude completion of the study procedure; * pregnant or nursing female subjects.

Keywords: lung nodule lung lesion